Audited Financial Statements for the quarter and year ended on March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Integrated Proteins Limited's board approved audited standalone financial results for the quarter and year ended March 31, 2025, with an unmodified opinion from auditor B. B. Gusani & Associates. Net profit for FY25 rose sharply to ₹21.29 lakhs from ₹6.92 lakhs in FY24, roughly tripling year-on-year. The company raised ₹1,744.88 lakhs via a preferential issue in January-February 2025, earmarked for capital expenditure (₹1,058.50 lakhs), working capital and general corporate purposes. There are no outstanding loan defaults. However, operating cash flow swung deeply negative to ₹(2,214.89) lakhs compared to ₹(5.94) lakhs in the prior year, driven largely by a sharp increase in other current assets to ₹3,231.85 lakhs.
The triple-digit PAT growth is positive on paper, but the steep negative operating cash flow and ballooning current assets suggest working capital is tied up, raising concerns about cash quality of profits. Shareholders should watch how the ₹17.25 crore raised via the preferential issue is deployed and whether trade payables and current asset build-up normalize in coming quarters.